Vinaora Nivo Slider

The Cardno ChemRisk View

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Archives
    Archives Contains a list of blog posts that were created previously.
  • Login
    Login Login form
Recent blog posts
Posted by on in Centers of Excellence

Posted on behalf of Rachel Novick and Alison Bowman. 

...
Continue reading
Hits: 223
Rate this blog entry:

Posted by on in Centers of Excellence
Posted on behalf of Kevin Towle

Silicone breast implants have been used for augmentation or reconstructive breast surgeries since the 1960s. However, as their popularity skyrocketed, concerns began to arise regarding a potential link between the implants and autoimmune or connective tissue diseases. Numerous studies were conducted on this issue in the 1980s and beyond, yielding mixed results. In 1992, the FDA issued a moratorium on silicone implants for safety assessment, and this ban remained in effect until 2006. Today, silicone implants are used in 84% of breast augmentation surgeries. According to the American Society of Plastic Surgeons, there were approximately 243,600 silicone breast augmentations in 2016.

During the FDA's moratorium, in 2000, a meta-analysis was conducted that examined 20 studies between 1984 and 1999. This analysis found no association between silicone breast implants and autoimmune disease. Since then, tools for autoimmune disease diagnosis have improved. Subsequent studies utilizing these tools found positive associations in previously unexamined cohorts, which demonstrated a need for an updated meta-analysis to quantitatively measure any association between silicone implants and autoimmune disease.

In 2016, Cardno ChemRisk conducted a meta-analysis of the results of 20 cohort and nine case control studies. Silicone breast implants were associated with a non-statistically significant decreased risk for all connective tissue diseases, meta-RR 0.87 (95% CI: 0.62-1.21). When stratified by disease, silicone breast implants were associated with a non-statistically significant increased risk of sclerosis, meta-RR 1.14 (0.75-1.74), and a non-statistically significant decreased risk of rheumatoid arthritis, meta-RR 0.75 (95% CI: 0.52-1.08), and systemic lupus erythematosus, meta-RR 0.90 (95% CI: 0.43-1.87). These findings suggest that silicone breast implant exposure is not associated with autoimmune disease among women.

If you would like to receive more information on this topic, please contact Dr. Andrew Monnot
Hits: 214
Rate this blog entry:
Posted by on in Centers of Excellence
Posted on behalf of Angela Perez, PhD and Fian Louie

In a report published by the Coalition for Safer Food Processing and Packaging (CSFPP), 30 cheese products, including dry cheese found in macaroni and cheese packets, were tested for 13 phthalates. Di(2-ethylhexyl) phthalate, or DEHP, was found at detectable levels in 93 percent of all samples tested, making it the most frequently detected phthalate. A synopsis of the CSFPP report was recently published in the New York Times on July 12, 2017.

DEHP is one of the most extensively used phthalates worldwide. The majority of DEHP is used as a plasticizer for flooring, waterproofing, cable sheathing/insulation, PVC, epoxy and polyurethane products; it is also used in fragrance bases for perfumery and cosmetic products. Several phthalates, including DEHP and many others that were tested by the CSFPP, are legal through the FDA for use as indirect food additives or as paper and paperboard components (for example, see: 21 CFR 176).

Cardno ChemRisk previously performed a risk assessment of DEHP in which 47 varieties of cheese sold in California from 31 companies were tested. Based on the sampling results, we performed a human health risk assessment to compare the potential human exposure levels to Prop 65 levels set at the time of the project. Based on our results, we concluded that the DEHP concentrations measured in California cheeses did not exceed the Proposition 65 NSRL (No Significant Risk Level, or the daily intake level posing a 1/100,000 lifetime risk of cancer).

Per the recent CSFPP report, the concentration of DEHP across all 30 products tested ranged from less than one microgram per kilogram (µg/kg) product weight to 165 µg/kg product weight, or parts per billion. The average DEHP concentration was 50 micrograms DEHP per kilogram product weight (assuming the products below the LOQ are zero). The NSRL adopted for DEHP under Proposition 65 is 310 micrograms per day (µg/day) for oral exposure (Cal/EPA 2002). The MADLs (Maximum Allowable Dose Level, or the level at which a chemical would have no observable effect even if an individual were exposed to 1,000 times that level) adopted for DEHP are 410 µg/day for adults, and 58 µg/day for infant boys (29 days-24 months) via oral exposure (Cal/EPA 2005; OAG). To put this in perspective, a cheese packet in a box of macaroni is approximately 1/3 cup or about 38 grams. Assuming an individual eats an entire box of macaroni and cheese and that the cheese mix contains the maximum concentration of DEHP reported by CSFPP for this product category (165 µg/kg product weight), then that person would consume a total of 6 µg of DEHP. This is nearly 10 times less than the MADL for infant boys and over 50 times less than the NSRL for adults.

For any questions, or if you need further information, regarding our risk assessment capabilities, please contact Drs. Angela Perez or Rachel Novick.
Hits: 555
Rate this blog entry:

Posted by on in Centers of Excellence
Two of our scientists, Drs. Marisa Kreider and Denise Hill, will be presenting at a webinar titled "Risk Communication - It's Not Just About the Facts", hosted by the Society of Petroleum Engineers (SPE), on Tuesday, July 25th at 9:30AM (EDT). The presenters will be discussing various aspects of risk communication. Dr. Hill will be covering risk perception, specifically public concerns regarding land-based fracking operations, and Dr. Kreider's talk will be focused around the science of risk assessment and the challenges hazard-driven regulatory agendas are causing with respect to risk communication.  You can register for this webinar here

Hits: 252
Rate this blog entry:
0

Posted by on in Centers of Excellence
We are pleased to share with you an article our colleagues recently published in Inhalation Toxicology, titled “Cosmetic talc as a risk factor for pleural mesothelioma: a weight of evidence evaluation of the epidemiology.

In this paper, the authors pooled all of the mesothelioma studies of cosmetic talc miners and determined that, if in fact mesothelioma incidence had been significantly increased in these cohorts, it would have been detected using standard statistical techniques.  No increase at all was observed, and in fact there wasn’t a single reported case of mesothelioma in any cohort. 

The impetus for this study was a statement by EPA (in the early 1990’s) that the existing data were not sufficiently powerful to assess whether the miners were at risk.  Our analysis, which relies primarily on findings published since that time shows that there is now sufficient power to make such a determination.  As described in the paper, our findings are consistent with the fact that no pleural mesotheliomas have been observed in patients treated with very high doses of cosmetic talc placed directly in the pleura (“pluerodesis”).

Because miners were exposed to cosmetic talc at levels much higher than those associated with the use of cosmetic talc products, we conclude this is evidence that product use is highly unlikely to be a risk factor for mesothelioma.

If you have any questions or would like further information, please contact Dr. Stacey Benson.
Hits: 897
Rate this blog entry:

The Cardno ChemRisk View

We're glad you decided to check us out.

Cardno ChemRisk is a respected scientific consulting firm headquartered in San Francisco with locations and consultants across the U.S. While our website provides a formal look at our capabilities, the Cardno ChemRisk View provides an informal voice too. Various Cardno ChemRisk consultants will be sharing news and views about current trends, happenings and methodologies in the industry. We’ll also highlight activities of interest at Cardno ChemRisk, within confidentiality restrictions of course.

The intent is to keep you informed and enable productive conversations, so please join in and get to know our staff and what makes our people unique. We are enthusiastic about the blogging experience and hope you will return often to learn and share. Stay tuned by subscribing to our blog or clicking on the RSS feed.